Previous
Previous

Endocrine Disruptor assessment for (3E)-1,7,7-trimethyl-3-(4-methylbenzylidene)bicyclo[2.2.1]heptan-2-one concluded

Next
Next

11th recommendation for inclusion in the Authorisation List